Many researches have revealed that the status of PR has great prognostic effect on breast cancer and patients with estrogen receptor-positive/progesterone receptor-positive (ER+/PR +) have better outcomes than patients with estrogen receptor-positive/progesterone receptor-negative (ER+/PR−)5–7. This evidence concerns the gene ESR1 and breast carcinoma.